NEW YORK, Nov 18 (Reuters) - Shares of Eli Lilly and Co (LLY.N: Quote, Profile, Research) could dip another 10 percent as mixed results for its anti-clotting drug dim the company’s sales outlook, according to financial newspaper Barron’s.
NEW YORK, Nov 18 (Reuters) - Shares of Eli Lilly and Co (LLY.N: Quote, Profile, Research) could dip another 10 percent as mixed results for its anti-clotting drug dim the company’s sales outlook, according to financial newspaper Barron’s.
